CareDx, Inc (CDNA)
Market Cap | 776.05M |
Revenue (ttm) | 275.11M |
Net Income (ttm) | -183.19M |
Shares Out | 52.08M |
EPS (ttm) | -3.41 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 398,533 |
Open | 15.30 |
Previous Close | 15.38 |
Day's Range | 14.80 - 15.34 |
52-Week Range | 4.80 - 17.03 |
Beta | 1.78 |
Analysts | Buy |
Price Target | 17.25 (+15.77%) |
Earnings Date | Aug 6, 2024 |
About CDNA
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used t... [Read more]
Financial Performance
In 2023, CareDx's revenue was $280.32 million, a decrease of -12.89% compared to the previous year's $321.79 million. Losses were -$190.28 million, 148.4% more than in 2022.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for CDNA stock is "Buy." The 12-month stock price forecast is $17.25, which is an increase of 15.77% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/s/z/press1-2458592.jpg)
Landmark Independent Publication in Nature Medicine Validates CareDx AlloView AI-Enabled Risk Prediction Model and Demonstrates AlloSure Kidney Detects Subclinical Rejection in Stable Patients
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...
![](https://cdn.snapi.dev/images/v1/d/a/press18-2453293.jpg)
AI Integration and Real-World Utility of CareDx Portfolio Highlighted in New Data at the 2024 American Transplant Congress
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinical...
![](https://cdn.snapi.dev/images/v1/u/g/press5-2451458.jpg)
CareDx Reiterates Position that it Does Not Infringe the ‘544 Patent, Injunction Motion is Irrelevant
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...
![](https://cdn.snapi.dev/images/v1/4/c/conf19-2451205.jpg)
CareDx to Participate in Upcoming Investor Conferences
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...
![](https://cdn.snapi.dev/images/v1/b/q/press7-2436020.jpg)
Landmark Study Shows CareDx's HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinical...
![](https://cdn.snapi.dev/images/v1/i/n/press13-2422592.jpg)
CareDx Reports First Quarter 2024 Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights Reported first quarter reven...
![](https://cdn.snapi.dev/images/v1/l/y/press5-2410110.jpg)
CareDx Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinical...
![](https://cdn.snapi.dev/images/v1/q/n/conf14-2398239.jpg)
CareDx to Report First Quarter 2024 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...
![](https://cdn.snapi.dev/images/v1/a/c/press4-2381381.jpg)
CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinical...
![](https://cdn.snapi.dev/images/v1/o/i/press14-2374511.jpg)
CareDx Appoints John W. Hanna as its New President and Chief Executive Officer
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinical...
![](https://cdn.snapi.dev/images/v1/w/w/press7-2362634.jpg)
CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...
![](https://cdn.snapi.dev/images/v1/i/2/press8-2318693.jpg)
CareDx Appoints Bryan Riggsbee to Its Board of Directors
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinical...
![](https://cdn.snapi.dev/images/v1/e/8/press4-2299542.jpg)
CareDx Announces Fourth Quarter and Full Year 2023 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) today reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter and Full Year 2023 Highligh...
![](https://cdn.snapi.dev/images/v1/d/1/press4-2297021.jpg)
CareDx to Participate in the Raymond James & Associates' 45th Annual Institutional Investors Conference
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinical...
![](https://cdn.snapi.dev/images/v1/b/4/conf11-2287049.jpg)
CareDx to Report Fourth Quarter and Full Year 2023 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...
![](https://cdn.snapi.dev/images/v1/b/s/press12-2285554.jpg)
CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) —The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...
![](https://cdn.snapi.dev/images/v1/j/q/press17-2247588.jpg)
CareDx Issues Statement in Patent Infringement Case
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...
![](https://cdn.snapi.dev/images/v1/s/z/press12-2226561.jpg)
CareDx Adds to AlloSure Kidney and HeartCare Utility and Clinical Data at 2024 American Society of Transplant Surgeons Winter Symposium
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...
![](https://cdn.snapi.dev/images/v1/0/g/press14-2221892.jpg)
CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2023
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...
![](https://cdn.snapi.dev/images/v1/y/4/press6-2201560.jpg)
CareDx Joins Forces with the National Foundation for Transplants to Improve Post-Transplant Medication Adherence
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...
![](https://cdn.snapi.dev/images/v1/7/w/press14-2148082.jpg)
CareDx Reports Third Quarter 2023 Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...
![](https://cdn.snapi.dev/images/v1/s/c/conf11-2137696.jpg)
CareDx to Report Third Quarter 2023 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...
![](https://cdn.snapi.dev/images/v1/m/a/press18-2134139.jpg)
CareDx Announces CEO Transition
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...
![](https://cdn.snapi.dev/images/v1/b/0/press8-2106155.jpg)
CareDx Presents New Data at the American Society for Histocompatibility and Immunogenetics Annual Meeting
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...
![](https://cdn.snapi.dev/images/v1/3/6/press14-2088704.jpg)
CareDx Issues Statement on Supreme Court Decision Regarding Stanford-Licensed Patents
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...